EMA to investigate Covid-19 treatment

A potential oral Covid-19 treatment will be evaluated by the European Medicines Agency after showing promising results from a phase III trial.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

The European Medicines Agency (EMA) will commence a rolling review of the Covid-19 treatment molnupiravir, it reports on Thursday.

Molnupiravir is an oral drug developed by the US-based pharmaceutical company Merck. According to the company, the treatment can halve the risk of hospitalization or death for Covid-19 infected people.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs